Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL 1020 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BL 1020 | DRUG | - |
| Perphenazine | DRUG | - |
Inclusion Criteria: 1. Voluntarily signed written informed consent agreement approved by the Independent Ethics Committee (IEC) after explanation of the nature and objectives of the study and prior to any study specific procedure. 2. Healthy male subjects between the age of 21 and 35 (inclusive). 3...
BL 1020 is an investigational small molecule being studied for the treatment of schizophrenia and schizoaffective disorder. It has also been evaluated in healthy subjects in early-phase trials. The drug is not approved and remains in clinical development.
BL 1020 is being developed by BioLineRx Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BLRX. The company has sponsored clinical trials of the drug in schizophrenia and related conditions.
BL 1020 is in Phase 1 clinical development. While some completed trials were Phase 2 studies, the most advanced stage reported for the drug is Phase 1. It is an investigational agent and has not received regulatory approval.
BL 1020 has been studied in several completed trials, including NCT00480246, a PET study in healthy male subjects; NCT00480571, a safety and tolerability study in schizophrenia; NCT00567710, a randomized Phase II study; and NCT00722176, a long-term extension study.
BL 1020 targets the dopamine D2 receptor, as assessed in a PET study using [11C]raclopride to measure receptor occupancy in the brain after single doses of the drug. This mechanism is relevant to its investigation in schizophrenia.
BL 1020 is not the same as perphenazine. In a clinical trial, BL-1020 was compared with perphenazine to assess dopamine D2 receptor occupancy in healthy subjects. They are distinct compounds, with perphenazine serving as a reference in that study.